Literature DB >> 20518610

Teratogenic effects of antiepileptic drugs.

Denise S Hill1, Bogdan J Wlodarczyk, Ana M Palacios, Richard H Finnell.   

Abstract

Many antiepileptic drugs (AEDs) have therapeutic applications that extend beyond epilepsy to include neuropathic pain, migraine headaches and psychiatric disorders. The risk of some AEDs has been clearly established, but for newer drugs, small sample sizes and polytherapy exposures preclude a conclusive determination of their teratogenic potential. Most women with epilepsy will require AED therapy throughout their entire pregnancy to control seizures; the vast majority of pregnancies in women with epilepsy have positive outcomes. A conservative estimate suggests that AED monotherapy doubles, and polytherapy triples, the risk for major congenital malformations. Furthermore, while evidence is still accruing, recent investigations suggest that exposure to select AEDs results in altered cognitive function later in development. There is no evidence to suggest that additional folic acid supplementation ameliorates the increased risk of congenital malformations conferred by in utero AED exposure.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20518610      PMCID: PMC2970517          DOI: 10.1586/ern.10.57

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  147 in total

1.  Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry.

Authors:  F J E Vajda; A Hitchcock; J Graham; C Solinas; T J O'Brien; C M Lander; M J Eadie
Journal:  Eur J Neurol       Date:  2006-06       Impact factor: 6.089

2.  Diphenylhydantoin teratogenicity in rats.

Authors:  R D Harbison; B A Becker
Journal:  Toxicol Appl Pharmacol       Date:  1972-06       Impact factor: 4.219

3.  Relation of dosage and time of administration of diphenylhydantoin to its teratogenic effect in mice.

Authors:  R D Harbison; B A Becker
Journal:  Teratology       Date:  1969-11

4.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.

Authors:  M Göttlicher; S Minucci; P Zhu; O H Krämer; A Schimpf; S Giavara; J P Sleeman; F Lo Coco; C Nervi; P G Pelicci; T Heinzel
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

5.  Teratogenicity of diphenylhydantoin in the New Zealand white rabbit.

Authors:  R M McClain; L Langhoff
Journal:  Teratology       Date:  1980-06

6.  Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register.

Authors:  S Hunt; J Craig; A Russell; E Guthrie; L Parsons; I Robertson; R Waddell; B Irwin; P J Morrison; J Morrow
Journal:  Neurology       Date:  2006-11-28       Impact factor: 9.910

Review 7.  Pregnancy registries in epilepsy: a consensus statement on health outcomes.

Authors:  K J Meador; P B Pennell; C L Harden; J C Gordon; T Tomson; P W Kaplan; G L Holmes; J A French; W A Hauser; P G Wells; J A Cramer
Journal:  Neurology       Date:  2008-08-13       Impact factor: 9.910

8.  Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives.

Authors:  Daniel Eikel; Alfonso Lampen; Heinz Nau
Journal:  Chem Res Toxicol       Date:  2006-02       Impact factor: 3.739

9.  Lack of relation of oral clefts to diazepam use during pregnancy.

Authors:  L Rosenberg; A A Mitchell; J L Parsells; H Pashayan; C Louik; S Shapiro
Journal:  N Engl J Med       Date:  1983-11-24       Impact factor: 91.245

10.  In utero exposure to vigabatrin: no indication of visual field loss.

Authors:  Charlotte Lawthom; Philip E M Smith; John M Wild
Journal:  Epilepsia       Date:  2008-06-26       Impact factor: 5.864

View more
  29 in total

Review 1.  [Emergency medication during pregnancy].

Authors:  H Fink; S Pildner von Steinburg
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-02-02       Impact factor: 0.840

2.  Brief report novel mechanism for valproate-induced teratogenicity.

Authors:  Kristin Fathe; Ana Palacios; Richard H Finnell
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2014-07-26

Review 3.  Developmental effects of antiepileptic drugs and the need for improved regulations.

Authors:  Kimford J Meador; David W Loring
Journal:  Neurology       Date:  2015-10-30       Impact factor: 9.910

4.  Bicuspid aortic valve and severe aortic stenosis in a newborn exposed to carbamazapine during pregnancy.

Authors:  Zehra Karataş; Ahmet Karataş; Tülay Özlü; Sevil B Goksugur; Birgül Varan
Journal:  J Turk Ger Gynecol Assoc       Date:  2014-08-08

5.  Ameliorative effects of supplemental folinic acid on Lamotrigine-induced fetal malformations in the mouse.

Authors:  Y M Abdulrazzaq; M Shafiullah; J Kochyil; R Padmanabhan; S M A Bastaki
Journal:  Mol Cell Biochem       Date:  2018-01-23       Impact factor: 3.396

6.  Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs.

Authors:  Pierre-Olivier Blotière; Fanny Raguideau; Alain Weill; Elisabeth Elefant; Isabelle Perthus; Véronique Goulet; Florence Rouget; Mahmoud Zureik; Joël Coste; Rosemary Dray-Spira
Journal:  Neurology       Date:  2019-06-12       Impact factor: 9.910

7.  Facial Dysmorphism: An Unreported Teratogenicity with Levetiracetam.

Authors:  Jyotsana Gupta; Sandhya Jain; Shalini Rajaram; Neerja Goel; Bindiya Gupta
Journal:  J Clin Diagn Res       Date:  2017-01-01

Review 8.  Antiepileptic drugs and pregnancy outcomes.

Authors:  Bogdan J Wlodarczyk; Ana M Palacios; Timothy M George; Richard H Finnell
Journal:  Am J Med Genet A       Date:  2012-06-18       Impact factor: 2.802

Review 9.  Medical and psychological risks and consequences of long-term opioid therapy in women.

Authors:  Beth D Darnall; Brett R Stacey; Roger Chou
Journal:  Pain Med       Date:  2012-08-20       Impact factor: 3.750

Review 10.  Impact of early life exposure to antiepileptic drugs on neurobehavioral outcomes based on laboratory animal and clinical research.

Authors:  Kevin G Bath; Helen E Scharfman
Journal:  Epilepsy Behav       Date:  2013-01-08       Impact factor: 2.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.